Vapotherm (VAPO)

Executive Summary

Vapotherm is a medical technology company specializing in high velocity therapy (HVT) for respiratory support. Its proprietary devices deliver heated, humidified, and oxygenated gas at high flow rates, offering a non-invasive alternative to traditional oxygen therapy and mechanical ventilation. The company serves both hospital and home care settings, addressing a growing market driven by the prevalence of chronic respiratory diseases such as COPD, asthma, and COVID-19-related complications. Vapotherm’s technology is differentiated by its ability to improve patient comfort and outcomes while reducing the burden on healthcare systems. Despite competitive pressures from larger medtech firms and evolving standards of care, Vapotherm has carved a niche with its innovative HVT platform. The company’s strategic focus on expanding indications and home care penetration positions it for sustained growth, though near-term profitability remains challenged by R&D and commercialization costs. With a lean operating structure and a clear value proposition, Vapotherm is poised to capitalize on the increasing demand for non-invasive respiratory support solutions.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance for Expanded Home Use of Precision Flow70% success
• Q4 2026Launch of Next-Generation High Velocity Therapy Device60% success
• Q2 2026Positive Top-Line Results from Pivotal COPD Trial50% success